Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIT Regimen (Methotrexate, Ibrutinib, Temozolomide) in Newly Diagnosed PCNSL
NCT04514393Phase 2Unknown
- Start
- Oct 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in primary central nervous system lymphoma (PCNSL). Status: unknown.
02
Drugs
ibrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04514393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514393.